Bruker logged a 1.4% change during today's afternoon session, and is now trading at a price of $78.45 per share. The S&P 500 index moved -0.0% and the Nasdaq posted a -1.0% change.
Bruker shares moved 24.1% over the last 52 weeks, with a high of $79.33 and a low of $48.42. During this time, the stock outperformed the S&P 500 index by 33.0%. As of January 2022, the company's 50-day average price is $73.0. Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The large-cap Industrials company has 8,525 full time employees and is based in Billerica, MA. Bruker has returned a 0.3% dividend yield over the last 12 months.
The Company Has a Steady Stream of Positive Cash Flows:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (MM) | $2,073 | $1,988 | $2,418 | $2,531 |
| Revenue Growth | n/a | -4.11% | 21.66% | 4.67% |
| Gross Margins | 48.0% | 47.3% | 50.0% | 51.6% |
| Gross Margins Growth | n/a | -1.46% | 5.71% | 3.2% |
| Operating Margins | 14.4% | 13.2% | 17.4% | 18.0% |
| Operating Margins Growth | n/a | -8.33% | 31.82% | 3.45% |
| Net Margins | 9.51% | 7.94% | 11.46% | 11.72% |
| Net Margins Growth | n/a | -16.51% | 44.33% | 2.27% |
| Earnings Per Share | $1.26 | $1.02 | $1.81 | $1.99 |
| EPS Growth | n/a | -19.05% | 77.45% | 9.94% |
| Diluted Shares (MM) | 157 | 155 | 153 | 147 |
| Free Cash Flow (MM) | $140 | $235 | $190 | $145 |
| FCF Growth | n/a | 67.38% | -18.98% | -23.74% |
| Capital Expenditures (MM) | -$73 | -$97 | -$92 | -$129 |
| Net Debt / EBITDA | 0.36 | 0.47 | 0.52 | 1.05 |
Bruker Is Too Expensive at Current Levels:
Compared to the Industrials sector's average of 20.49, Bruker has a trailing twelve month P/E ratio of 39.4 and, according to its EPS guidance of 2.89, an expected P/E ratio of 27.1. Bruker's PEG ratio is 1.4 based on its 0.1806072871670663% compound average growth rate of historical and projected earnings per share. This implies that the company's shares are fairly valued.
Bruker's P/B ratio is 10.4 compared to its sector average of 3.78. The company is likely overvalued in terms of its equity. The company's shares are currently trading 387.4% above their fair value as expressed by Benjamin Graham's formula:
√(22.5 * 4-year average EPS * book value per share) = √(22.5 * 1.52 * 7.576) = $16.1
Bruker Benefits From Positive Market Indicators:
9 analysts are following Bruker and have set target prices ranging from $63.0 to $90.0 per share. On average, they have given the company a rating of buy. At the current price of $78.45, BRKR is trading -1.25% away from its average analyst target price of $79.44 per share, implying an analyst consensus of some upside potential for the stock.
The company has an average amount of shares sold short since 5.4% of the company's shares are tied to short positions. Institutions own 71.9% of Bruker's shares, while the insider ownership rate stands at 32.86%. The biggest shareholder is T. Rowe Price Investment Management, Inc. with a 11% stake in the company worth approximately $1,284,080,846.
